Madrid, Spain – February 12, 2025 – Micro-Tech has officially completed the acquisition of a 51% stake in Creo Medical S.L.U. (CME), a wholly owned subsidiary of Creo Medical Group plc. The transaction was finalized at the notary office in Madrid, representing a major step forward in Micro-Tech’s global strategy and a significant milestone in the company’s international development journey.

Paving the Way for Strategic Growth

With a longstanding commitment to innovation and quality, Micro-Tech has steadily grown its presence in the medical device industry. The acquisition was completed through Micro-Tech’s wholly owned subsidiary, Micro-Tech (NL) International B.V., securing a controlling interest in CME. This transaction strengthens Micro-Tech’s global footprint and enhances its ability to serve healthcare professionals and patients worldwide.

Joining Forces to Maximize Synergies

Creo Medical, headquartered in the UK and listed on the London Stock Exchange (LSE: CREO), specializes in the development and commercialization of advanced minimally invasive surgical devices for endoscopic procedures. Its flagship product, CROMA, is an electrosurgical platform that delivers both microwave and bipolar RF energy through a single accessory port—offering greater precision and efficiency for therapeutic endoscopy.

CME, as Creo Medical’s distribution arm, markets both Creo-branded products and those from other leading medical device companies in areas such as gastroenterology, urology, pulmonology, and single-use endoscopy. In 2023, endoscopic consumables and single-use scopes accounted for nearly 70% of CME’s revenue.

Mr. Long Xiaohui, Chairman of Micro-Tech, commented:

“As a leading Chinese manufacturer of endoscopic diagnostic and therapeutic devices, Micro-Tech has been actively expanding its global distribution channels and seeking strategic partnerships with innovative companies. CME is a key distributor in the European medical device market, with a highly complementary product portfolio and sales network.

This acquisition allows us to introduce more high-quality Micro-Tech products into CME’s portfolio, support Creo Medical’s R&D and market expansion, and create new growth opportunities for all parties involved. Micro-Tech, Creo Medical, and CME share a common strategic vision and a unified mission—to deliver better healthcare solutions for patients and physicians.”

Accelerating Global Reach

The acquisition of CME strengthens Micro-Tech’s market presence across Western Europe. With CME’s extensive sales network—serving nearly 5,000 healthcare institutions across the UK, Spain, France, and beyond—Micro-Tech gains a solid platform to bring its innovative products to more regions in Europe and accelerate global business development.

Building a Global Brand, Leading the Future

This acquisition marks a significant step in Micro-Tech’s internationalization strategy. It reflects the company’s long-term commitment to becoming a trusted global brand in minimally invasive medical technology. With the integration of CME, Micro-Tech will continue to optimize its international network, expand its brand presence in key markets, and bring cutting-edge technologies to more patients around the world.

The successful acquisition of CME signals the beginning of a new chapter for Micro-Tech. With strong collaboration among all parties, we are confident that this partnership will unlock new growth opportunities and inject fresh momentum into our global expansion.